CTSO:NASDAQ
Cytosorbents Corp
$3.06
arrow_downward
-0.97%(-0.030) 1D
Okt 15, 4:00:00 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa CTSO...
Buksan
$2.96
Mataas
$3.09
Mababa
$2.84
Mkt. cap
9.64M
Avg. na dami
245.34K
Dami
0.00
Mataas nang 52-wk
$18.80
Mababa nang 52-wk
$2.84
EPS
-$5.80
Beta
1.37
Mga natitirang share
3.15M
Bilang ng mga empleyado
129
Buksan
$2.96
Mataas
$3.09
Mababa
$2.84
Mkt. cap
9.64M
Avg. na dami
245.34K
Dami
0.00
Mataas nang 52-wk
$18.80
Mababa nang 52-wk
$2.84
EPS
-$5.80
Beta
1.37
Mga natitirang share
3.15M
Bilang ng mga empleyado
129
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
MarketBeat
·
15 minuto ang nakalipas
PDD Holdings Inc. Sponsored ADR (NASDAQ:PDD) Stock Rated "Hold" by Wall Street Brokerages
Yahoo Finance
·
1 oras ang nakalipas
XRP Treasury Company Evernorth Just Went Public on Nasdaq. Here's How It Could Impact the Price of XRP.
Benzinga
·
16 minuto ang nakalipas
Stock Market: Will S&P 500 Open Up or Down Today?
Seeking Alpha
·
18 oras ang nakalipas
SPYI: The Fed Raised Rates, The Gap Grew Wider And My Favorite S&P500 Income ETF Delivered
Profile
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.
CytoSorbents sells a cytokine adsorbing column — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood.
The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns, which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects.
CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins. Wikipedia
Tungkol sa Cytosorbents Corp